
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery portfolio following the two companies’ …

BenevolentAI has announced that it has appointed Dr Joerg Moeller MD PhD as chief executive officer and executive board member …

Health and drug development-focused artificial intelligence firm BenevolentAI has announced that former UK Minister for Internet Security and Safety Joanna …

BenevolentAI, a London based drug discovery biotech, has revealed that a $115 million financing round now sees the company valued …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

